The Gravitate Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life.
engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.
to provide a key piece to advance this vision: the Gravitate Lens (G-Lens), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs.
1 – develop an integrated, digital, user-centric health information solution with two-way communication for the public so that health information from a set of trusted sources is available and understandable (such as package leaflet content) and EHR-IPS (International Patient Summary).
2 – promote adherence to treatment, safer use of medication (Pharmacovigilance), better health outcomes and quality of life through improved availability and understanding of health information from trusted sources & minimize risk through optimal use of available health information.
Gravitate Health services and G-lens will be developed and tested within the project, using an evaluation framework to test the efficiency, efficacy, and safety of Gravitate-Health services.
The Gravitate Health is a public – private partnership with 40 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.
Gravitate Health started at 01 November 2020
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu